PepGen Inc.
PepGen Inc. is a U.S.-based clinical-stage biotechnology company developing oligonucleotide therapeutics through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. The company was founded around technology spun out from the University of Oxford and MRC and is focused on advancing treatments for severe neuromuscular and neurologic diseases, including myotonic dystrophy type 1.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2021–2025
Liiketoiminta
Osuus liikevaihdostaCell-penetrating peptide delivery technology used to improve oligonucleotide uptake and tissue delivery.
PGN-EDODM1, an investigational therapy targeting the underlying cause of DM1.
Additional oligonucleotide candidates for severe neuromuscular and neurologic diseases.
Internal discovery, preclinical testing, and clinical development activities supporting the pipeline.
Asiakkaat
PepGen does not currently have commercial customers because its programs are still in development. Its future buyers, if approved, would likely be specialty physicians, hospitals, and treatment centers serving patients with rare neuromuscular and neurologic diseases. The company also expects potential commercialization to involve payers and, in some markets, strategic partners or distributors.
Patients with severe neuromuscular and neurologic diseases who would receive the therapy if approved.
Neuromuscular specialists and key opinion leaders who influence treatment adoption in rare disease markets.
Hospitals, clinics, and treatment centers that would administer or dispense the product.
Insurers and reimbursement bodies that affect access, pricing, and uptake after approval.
Potential distributors, contract sales forces, or strategic collaborators outside the U.S.
Strategia
PepGen's strategy is centered on advancing its EDO platform and lead DM1 program through clinical development toward regulatory approval. The company also aims to expand the platform into additional severe diseases with high unmet need, while deciding whether future commercialization should be direct in the U.S. or partner-led in other territories.
The lead program is the main value driver and the basis for any future approval or commercialization.
A broader pipeline reduces dependence on a single asset and increases the value of the EDO technology.
Rare-disease launch strategy must match the size and concentration of the prescriber base.
Maantiede
PepGen is headquartered in Boston, Massachusetts, and is incorporated in Delaware, with origins in the U.K. through PepGen Limited. The company currently has no commercial infrastructure in any geography, but it expects future commercialization to begin in the U.S. and potentially expand to selected other territories through partners or its own sales organization.
Riskit
PepGen is highly dependent on the success of a single lead candidate and on the outcome of clinical and regulatory development. As a clinical-stage biotech, it also faces financing risk, manufacturing and supplier concentration risk, and the possibility that its platform or product candidates do not show sufficient safety, efficacy, or commercial differentiation.
- Dependence on PGN-EDODM1Vaikutus: KriittinenTodennäköisyys: Korkea
The company states it is substantially dependent on the success of its lead product candidate.
Kohdistuu: Lead DM1 program
- Clinical and regulatory failureVaikutus: KriittinenTodennäköisyys: Korkea
If trials do not demonstrate adequate safety or efficacy, approval and commercialization may not occur.
Kohdistuu: All product candidates
- Financing and going-concern riskVaikutus: KriittinenTodennäköisyys: Korkea
The company expects to need additional capital and has disclosed substantial doubt about continuing as a going concern.
Kohdistuu: Corporate funding
- Single-source supplier dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Key components, API, and finished product manufacturing rely on limited suppliers.
Kohdistuu: Clinical and future commercial supply chain
- Intellectual property protectionVaikutus: KorkeaTodennäköisyys: Matala
The EDO platform depends on licensed patents, know-how, and enforceable IP rights.
Kohdistuu: Platform technology
- China and third-party manufacturing exposureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Some vendors operate outside the U.S., including in China, creating BIOSECURE and transition risk.
Kohdistuu: Clinical trial materials and development services
Kirjanpito
Harkinnanvaraiset erätClinical trial and manufacturing costs are estimated before invoices are finalized, affecting period expense timing.
Vaikutus: Can shift reported operating losses between quarters
Public-company equity awards create non-cash compensation expense that can be material for a biotech issuer.
Vaikutus: Affects operating loss and diluted share analysis
Interest income and valuation changes on money market and treasury holdings affect other income.
Vaikutus: Influences non-operating results
Management must evaluate whether available cash is sufficient for the next 12 months.
Vaikutus: Important for liquidity and financing risk disclosure
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Neurogene Inc.
NGNE · Pharmaceutical Preparations
Edgewise Therapeutics, Inc.
EWTX · Pharmaceutical Preparations
Ocugen, Inc.
OCGN · Biological Products, (No Diagnostic Substances)
NervGen Pharma Corp
NGEN · Pharmaceutical Preparations
Vistagen Therapeutics, Inc.
VTGN · Pharmaceutical Preparations
Vistagen Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on neuroscience disorders.
enGene Therapeutics Inc.
ENGN · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026